“OUR GOAL - Patient Safety"
OUR SUCCESS
We measure our success in contributions to scientific peer-reviewed journals:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Linares+O
http://www.ncbi.nlm.nih.gov/pubmed/?term=Boston+R
Our research receives no grant from any funding agency in the public, commercial, or not-for-profit sectors. We aim to serve humanity.
Our motto: "Art and science serving the community..."
OUR TEAM
We are a small creative group:
Oscar A. Linares, MD
David T. Daly, JD, MBA
William E. Schiesser, PhD, ScD
Jeffrey Fudin, BS, PharmD, FCCP, FASHP
Annemarie Daly Linares, MD, JD, FACP, HMDC
Raymond C. Boston, MS, PhD
We specialize translating in vivo pharmacogene-based pharmacokinetic data for drug dose regimen design and adjustment for patient safety.
We are integrating clinical pharmacokinetics, pharmacogenetics and quantitative CYP P450 polymorphic gene drug-drug Interactions (DDIs) technology for patient safety in dosing.
OUR SOLUTIONS
We study subject-level drug pharmacokinetics and pharmacodynamics (PKPD) using WinSAAM (http://www.winsaam.org/). We do population PKPD using WinSAAM's EMSA facility in SAAM31 and MONOLIX (http://www.lixoft.eu/) .
We use R for biostats and mixed modeling(http://www.r-project.org/)
We develop partial differential equation (PDE) models to study drug mass transport in vivo using the MOL.